Article content material
VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) — Xenon Prescribed drugs Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical firm, right now introduced the pricing of its upsized underwritten public providing of 8,461,542 widespread shares and, in lieu of widespread shares to sure traders, pre-funded warrants to buy as much as 769,230 widespread shares pursuant to its current shelf registration assertion. The widespread shares are being supplied at a public providing worth of $32.50 per widespread share and the pre-funded warrants are being supplied at a worth of $32.4999 per pre-funded warrant. The gross proceeds to Xenon from the providing, earlier than deducting underwriting reductions and commissions and different providing bills payable by Xenon, are anticipated to be roughly $300.0 million. As well as, Xenon has granted to the underwriters of the providing an possibility for a interval of 30 days to buy as much as a further 1,384,615 widespread shares on the public providing worth, much less the underwriting reductions and commissions. The providing is predicted to shut on or about December 4, 2023 topic to customary closing circumstances.
Commercial 2
Article content material
J.P. Morgan, Jefferies, BofA Securities, Stifel, and RBC Capital Markets are performing as joint book-running managers for the providing.
Article content material
An routinely efficient shelf registration assertion regarding the securities supplied within the public providing described above was filed with the Securities and Trade Fee (SEC) on October 4, 2021. The providing is being made solely via a written prospectus and prospectus complement that kind part of the registration assertion. A preliminary prospectus complement and accompanying prospectus regarding the providing have been filed with the SEC and can be found on the SEC’s web site at www.sec.gov. A ultimate prospectus complement and accompanying prospectus might be filed with the SEC. Copies of the ultimate prospectus complement and the accompanying prospectus, when accessible, may additionally be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Monetary Options, 1155 Lengthy Island Avenue, Edgewood, NY 11717, by phone at (866) 803-9204, or by e mail at prospectus-eq_fi@jpmchase.com; Jefferies LLC, Consideration: Fairness Syndicate Prospectus Division, 520 Madison Avenue, New York, NY 10022, by phone at (212) 284-2300, or by e mail at prospectus_department@jefferies.com; BofA Securities, Consideration: Prospectus Division, NC1-0220-02-25, 201 North Tryon Avenue, Charlotte, NC 28255-0001, or by e mail at dg.prospectus_requests@bofa.com; Stifel, Nicolaus & Firm, Integrated, Consideration: Syndicate, One Montgomery Avenue, Suite 3700, San Francisco, CA 94104, by phone at (415) 364-2720, or by e mail at syndprospectus@stifel.com; or RBC Capital Markets, LLC, Consideration: Fairness Capital Markets, 200 Vesey Avenue, New York, NY 10281, by phone at (877) 822-4089, or by e mail at equityprospectus@rbccm.com.
Commercial 3
Article content material
No securities are being supplied or bought, straight or not directly, in Canada or to any resident of Canada.
This press launch shall not represent a proposal to promote or the solicitation of a proposal to purchase the securities being supplied, nor shall there be any sale of the securities being supplied in any state or different jurisdiction wherein such supply, solicitation or sale could be illegal previous to the registration or qualification underneath the securities legal guidelines of any such state or different jurisdiction.
Secure Harbor Assertion
This press launch accommodates forward-looking statements inside the which means of Part 27A of the Securities Act of 1933 and Part 21E of the Securities Trade Act of 1934 and the Non-public Securities Litigation Reform Act of 1995 and Canadian securities legal guidelines. These forward-looking statements usually are not primarily based on historic truth and embody statements concerning the anticipated closing of the general public providing. These forward-looking statements are primarily based on present assumptions that contain dangers, uncertainties and different components which will trigger the precise outcomes, occasions or developments to be materially totally different from these expressed or implied by such forward-looking statements. These dangers and uncertainties, lots of that are past our management, embody, however usually are not restricted to, uncertainties associated to market circumstances and the completion of the general public providing on the anticipated phrases or in any respect, in addition to the opposite dangers recognized in our filings with the SEC and the securities commissions in British Columbia, Alberta and Ontario. These forward-looking statements converse solely as of the date hereof and we assume no obligation to replace these forward-looking statements, and readers are cautioned to not place undue reliance on such forward-looking statements.
Investor/Media Contact:
Jodi Regts
Xenon Prescribed drugs Inc.
Cellphone: 604.484.3353
Electronic mail: traders@xenon-pharma.com
Article content material